Key statistics
On Monday, Arcus Biosciences Inc (RCUS:NYQ) closed at 23.94, -9.32% below its 52-week high of 26.40, set on Dec 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 20.47 |
|---|---|
| High | 24.74 |
| Low | 20.29 |
| Bid | 23.33 |
| Offer | 24.69 |
| Previous close | 20.37 |
| Average volume | 1.28m |
|---|---|
| Shares outstanding | 125.35m |
| Free float | 88.35m |
| P/E (TTM) | -- |
| Market cap | 2.55bn USD |
| EPS (TTM) | -3.30 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Arcus Biosciences to Participate in Two Upcoming Investor Conferences
- Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
- Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
- Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
- Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
- Arcus Biosciences Announces New Employment Inducement Grants
More ▼
